da Silva Emerson Teixeira, de Andrade Gabriel Fernandes, Araújo Adriele da Silva, Almeida Ayla das Chagas, Coimbra Elaine S, de Souza Marcus Vinícius Nora
Fundação Oswaldo Cruz (Fiocruz), Instituto de Tecnologia em Fármacos Farmanguinhos, Rua Sizenando Nabuco 100, Manguinhos, Rio de Janeiro, 21041-250, Brazil.
Instituto de Química, Universidade Federal do Rio de Janeiro, Av. Brigadeiro Trompowsky, Rio de Janeiro, 21044-020, Brazil.
Acta Parasitol. 2020 Mar;65(1):203-207. doi: 10.2478/s11686-019-00146-5. Epub 2019 Dec 12.
Due to serious problems with the treatment of leishmaniasis all around the world, here is an urgent need in the search for new drugs that are more effective and safer for the treatment of the various forms of leishmaniasis. Actual therapy is limited and lacks sufficient efficacy due to incomplete elimination of the parasites form of patients. In this sense, we decided to evaluate, by first-time, a series of seventeen camphor hydrazone derivatives (2a-2p) against Leishmania amazonensis.
The compounds previously synthesized from camphor, an abundant natural compound, were evaluated in vitro against the extra and intracellular forms of Leishmania amazonensis, and murine macrophages.
The majority of compounds, fourteen, displayed activity against the intracellular form of the parasite (amastigote) with IC values ranging from 21.78 to 58.23 µM, being six compounds active for both forms of the parasite. The compound 2i exhibited higher activity against the amastigote form with the value of IC (21.78 µM) close to standard utilized miltefosine (12.74 µM) and selectivity index of at least 6.9. Six compounds displayed activity against promastigote form of Leishmania amazonensis 2g, 2j-2n (41.17-69.59 µM), with the compound 2m being the more active with IC = 41.17 µM, 1.9 times less active than the reference drug (IC = 21.39 µM). The compound 2m was the more selective to this form, with a selectivity index of at least 3.6. All the compounds were non-cytotoxic to macrophages.
Most compounds showed activity against amastigote form of Leishmania amazonensis, being that they were not cytotoxic to macrophage at the maximum tested concentration, showing the selective property of these compounds. Since amastigotes are the parasite stages that cause the disease in humans, these results highlight the antileishmanial effect of the compounds. This study indicates the possible development of candidates to leishmanicidal drugs from an abundant natural compound of easy access.
由于全球利什曼病治疗存在严重问题,迫切需要寻找对各种形式利什曼病治疗更有效、更安全的新药。目前的治疗方法有限,且由于未能完全清除患者体内的寄生虫,疗效不足。从这个意义上说,我们首次决定评估一系列17种樟脑腙衍生物(2a - 2p)对亚马逊利什曼原虫的作用。
对先前由丰富的天然化合物樟脑合成的化合物进行体外评估,以检测其对亚马逊利什曼原虫的胞外和胞内形式以及小鼠巨噬细胞的作用。
大多数化合物(14种)对寄生虫的胞内形式(无鞭毛体)具有活性,IC值范围为21.78至58.23 μM,其中6种化合物对两种寄生虫形式均有活性。化合物2i对无鞭毛体形式表现出更高的活性,IC值(21.78 μM)接近所用标准药物米替福新(12.74 μM),选择性指数至少为6.9。6种化合物对亚马逊利什曼原虫的前鞭毛体形式有活性,即2g、2j - 2n(41.17 - 69.59 μM),其中化合物2m活性最高,IC = 41.17 μM,活性比参考药物低1.9倍(IC = 21.39 μM)。化合物2m对这种形式的选择性更高,选择性指数至少为3.6。所有化合物对巨噬细胞均无细胞毒性。
大多数化合物对亚马逊利什曼原虫的无鞭毛体形式有活性,且在最高测试浓度下对巨噬细胞无细胞毒性,显示出这些化合物的选择性特性。由于无鞭毛体是在人类中引起疾病的寄生虫阶段,这些结果突出了化合物的抗利什曼原虫作用。本研究表明,有可能从一种易于获取的丰富天然化合物开发出利什曼icidal药物候选物。